Erschienen in:
07.08.2019 | Editorial
Al18F-NOTA-octreotide and 18F-SiFAlin-TATE: two ‘new kids on the block’ in somatostatin receptor imaging
verfasst von:
Karolien Goffin
Erschienen in:
European Journal of Nuclear Medicine and Molecular Imaging
|
Ausgabe 11/2019
Einloggen, um Zugang zu erhalten
Excerpt
Since their introduction in clinical routine, somatostatin receptor agonists (SSAs) labelled with the positron-emitting radionuclide gallium-68, collectively referred to as
68Ga-DOTA-peptides, have gradually replaced the use of
111In-DTPA-octreotide for imaging of the somatostatin receptor (SSTR) in patients with neuro-endocrine tumours (NETs). Apart from the specific advantages of PET over SPECT, such as a higher sensitivity (counts/Bq) and spatial resolution, the higher affinity of
68Ga-DOTA-peptides for the SSTR-subtype 2, which is the most overexpressed SSTR-subtype in NETs, offers an additional benefit in detecting SSTR-expressing lesions. Indeed, superior performance of
68Ga-DOTA-peptide-PET was demonstrated by several groups when comparing it head-to-head to
111In-DTPA-octreotide-SPECT in patients with NETs, with mainly a significantly higher sensitivity in detecting SSTR-overexpressing lesions [
1‐
4]. …